TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15927409
Drug: Treatment time
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment time as a continuous variable
Study: 15927409
Drug: Immediate concurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate concurrent chemoradiation (cisplatin-based)
Study: 15478385
Drug: Fluticasone propionate,
Normalized name: fluticasone propionate, micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone propionate, 2000 microg/d via a 750-mL primed spacer for 2 weeks
Study: 9247510
Drug: 400 IU
Normalized name: Vitamin D 400 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 IU of vitamin E, 500 mg of vitamin C, 12 mg of beta-carotene (mid-dose)
Study: 9247510
Drug: 800 IU
Normalized name: Vitamin E 800 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 IU of vitamin E, 1,000 mg of vitamin C, 24 mg of beta-carotene (high dose)
Study: 3552460
Drug: 10/10/10 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10/10/10 micrograms HA formulation
Study: 3552460
Drug: Monovalent A/Singapore/6/86-like
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent A/Singapore/6/86-like vaccine
Study: 3552460
Drug: Trivalent A/Mississippi,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent A/Mississippi, A/Chile, B/Ann Arbor influenza vaccine
Study: 3552460
Drug: A/Singapore vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: A/Singapore vaccine
Study: 27840374
Drug: α-lipoic acid
Normalized name: α-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: α-lipoic acid (LA) treatment
Study: 18553032
Drug: Ropivacaine 0.125%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.125% (15 ml)
Study: 18553032
Drug: Ropivacaine 0.0625%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.0625% plus 75 microg clonidine (15 ml)
Study: 16651056
Drug: Low-dose warfarin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose warfarin (mean INR 1.4, goal INR <2.0)
Study: 12816770
Drug: L-MUFA (7.8%
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-MUFA (7.8% of energy from MUFAs)
Study: 10853566
Drug: Bupivacaine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine administered preoperatively
Study: 7756096
Drug: Mizolastine 10
Normalized name: mizolastine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mizolastine 10 mg once daily for 8 days
Study: 7756096
Drug: Lorazepam 2
Normalized name: lorazepam 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam 2 mg single dose
Study: 2312774
Drug: Metoprolol CR/ZOK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol CR/ZOK 100-200 mg daily
Study: 31989459
Drug: 10% dextrose
Normalized name: Aminosyn II 4.25% in 10% Dextrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% dextrose solution
Study: 29390915
Drug: Infusion site
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion site failure detection algorithm
Study: 23987833
Drug: Trabectedin as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabectedin as second-line treatment (24-hour infusion every 3 weeks)
Study: 22534669
Drug: Pemetrexed (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed (500 mg/m²) + Cisplatin (75 mg/m²) followed by Gefitinib (250 mg/d)
Study: 22534669
Drug: Pemetrexed (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed (500 mg/m²) + Cisplatin (75 mg/m²) followed by Pemetrexed (500 mg/m²)
Study: 15671124
Drug: Citalopram (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (20 mg on days 1-8, 40 mg on days 8-15)
Study: 15671124
Drug: Sertraline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50 mg on days 1-8, 100 mg on days 8-15)
Study: 10494365
Drug: Metoclopramide (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (0.3 mg x kg‐1)
Study: 10494365
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of dimenhydrinate (1 mg x kg‐1) and metoclopramide (0.3 mg x kg‐1)
Study: 9005795
Drug: Ofloxacin 200
Normalized name: ofloxacin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin 200 mg once a day for medium urinary tract infections
Study: 9005795
Drug: Ofloxacin 100
Normalized name: ofloxacin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin 100 mg twice a day for 3 to 7 days for severe lower urinary tract infections
Study: 9005795
Drug: Ofloxacin 200
Normalized name: ofloxacin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin 200 mg twice a day for 7 to 10 days for severe upper urinary tract infections
Study: 9005795
Drug: Ofloxacin 50
Normalized name: levofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin 50 mg once a day for 6 months for frequent acute recurring infections
Study: 6788406
Drug: Ketotifen (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen (1 mg twice daily, orally)
Study: 6788406
Drug: Disodium cromoglycate
Normalized name: Disodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disodium cromoglycate (inhalation of 20 mg, four times daily)
Study: 6366148
Drug: Four-drug program
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-drug program (cyclophosphamide, vincristine, methotrexate, prednisone [COMP])
Study: 6366148
Drug: 10-drug program
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-drug program (LSA2-L2 modified)
Study: 22975616
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (5 cycles of fluorouracil and leucovorin)
Study: 22975616
Drug: Chemoradiation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoradiation therapy (1 cycle of FL, then 45 Gy radiation concurrently with 2 cycles of FL, followed by 2 cycles of FL)
Study: 19460762
Drug: Comfrey root
Normalized name: COMFREY ROOT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comfrey root extract ointment (4 g per application, three times a day)
Study: 19460762
Drug: Placebo ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ointment (4 g per application, three times a day)
Study: 19460762
Drug: Comfrey root
Normalized name: COMFREY ROOT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comfrey root extract ointment
Study: 10025472
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (100 mg daily) and Vitamin C (500 mg daily) for 15 weeks
Study: 2347518
Drug: Aspirin at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin at very ultra low dosage
Study: 373517
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nebulized atropine sulfate and isoproterenol
Study: 25746779
Drug: Low-dose computed
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose computed tomography
Study: 23904337
Drug: Sublingual lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual lorazepam (0.1 mg/kg, n = 234)
Study: 23904337
Drug: Intrarectal diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrarectal diazepam (0.5 mg/kg, n = 202)
Study: 21903893
Drug: Armodafinil (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Armodafinil (titrated to 250 mg daily in the morning)
Study: 19221726
Drug: Quercetin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin (500 mg, 3 times a day for 7 days)
Study: 17591036
Drug: Probiotics (Enterococcus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (Enterococcus faecalis T‐110, Clostridium butyricum TO‐A, and Bacillus mesentericus TO‐A) administered perioperatively, starting immediately after admission, 3 to 15 days before the operation, and continued until hospital discharge.
Study: 15040824
Drug: Calcium and
Normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium and Vitamin D Program (1000 mg of elemental calcium as calcium carbonate and 400 IU of vitamin D3 daily)
Study: 10632537
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg of styrene maleic acid neocarzinostatin in 4 ml of Lipiodol (Group A)
Study: 10632537
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of epirubicin in 4 ml of Lipiodol (Group B)
Study: 8211540
Drug: Enoxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxacin (400 mg oral)
Study: 8211540
Drug: Ceftriaxone (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (250 mg intramuscular)
Study: 3546170
Drug: Non-living promastigote
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-living promastigote vaccine
Study: 31682572
Drug: Internet-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered cognitive behavioral therapy (ICBT) blended with weekly real-time therapist chat sessions for 8 weeks
Study: 23808298
Drug: Ivabradine (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivabradine (dose titrated during 2 weeks)
Study: 23808298
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with ivabradine + atenolol (in half doses)
Study: 23808298
Drug: Ivabradine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivabradine (15 mg/day)
Study: 21861038
Drug: Transition to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transition to low-molecular-weight heparin (LMWH) - enoxaparin: 1 mg/kg 2x/day before ablation, and 0.5 mg/kg 2x/day after ablation
Study: 21861038
Drug: Maintenance of
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance of warfarin with therapeutic INR (between 2.0 and 3.0)
Study: 18444883
Drug: VCL‐CB01 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: VCL‐CB01 vaccine (1- or 5-mg doses) administered on a 0-, 2-, and 8-week schedule
Study: 18444883
Drug: VCL‐CB01 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: VCL‐CB01 vaccine (5-mg doses) administered on a 0-, 3-, 7-, and 28-day schedule
Study: 11269896
Drug: Local conjunctival
Normalized name: Sus scrofa conjunctiva preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local conjunctival immunotherapy (LCIT) with standardized dermatophagoides pteronyssinus (Dp) extracts, administered daily for 6 months at increasing concentrations starting from 10 AU/ml to a maintenance dose of 1,000 AU/ml.
Study: 11269896
Drug: Placebo treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment, administered daily for 6 months.
Study: 9109894
Drug: 16 mg/d
Normalized name: futibatinib 16 mg/day (4 mg x 4) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg/d tiagabine
Study: 9109894
Drug: 32 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 32 mg/d tiagabine
Study: 9109894
Drug: 56 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 56 mg/d tiagabine
Study: 3084705
Drug: Multiple-monitored electroconvulsive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-monitored electroconvulsive therapy (MMECT)
Study: 3084705
Drug: Conventional electroconvulsive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional electroconvulsive therapy (CECT)
Study: 30892820
Drug: NAFLD defined
Normalized name: refined almond oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: NAFLD defined using a liver‐spleen ratio (L/S ratio) ≤1.1 on unenhanced abdominal CT scanning
Study: 30892820
Drug: L/S ratio
Approvals — FDA: no, EMA: no, PMDA: no
Description: L/S ratio ≤1.1
Study: 30630798
Drug: Spinal-epidural anesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal-epidural anesthesia with intravenous injection of dexmedetomidine
Study: 23525418
Drug: Warfarin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin therapy (experienced vs naïve)
Study: 20597245
Drug: Nicotine gum
Normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine gum (4 mg, one stick per hour)
Study: 19075486
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (controls, 61 patients)
Study: 11099628
Drug: Cisapride (0.80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (0.80 mg/kg/day for group 1 and 2; 0.72 mg/kg/day for group 3)
Study: 2830968
Drug: Thymosin fraction
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymosin fraction V (60 mg/m2 s.c. twice weekly) during induction chemotherapy and radiation therapy
Study: 31515562
Drug: Serum neurofilament
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum neurofilament light chain (sNfL) levels measured using an ultrasensitive single‐molecule array assay (Simoa)
Study: 28463718
Drug: Computer-assisted cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-assisted cognitive remediation (CACR) therapy
Study: 23706259
Drug: Antibiotic group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic group (flomoxef sodium every 12 hours for 3 days)
Study: 23706259
Drug: Non‐postoperative antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non‐postoperative antibiotic group
Study: 21744744
Drug: Myo-inositol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myo-inositol (2 g) + Folic acid (200 microg)
Study: 11559340
Drug: Topical nasal
Normalized name: Nasal Inhalant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nasal drops dyed with methylene blue (0.1% v/v)
Study: 11559340
Drug: Topical aqueous
Normalized name: Pen-Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical aqueous sprays dyed with methylene blue (0.1% v/v)
Study: 9427455
Drug: Acellular pertussis
Normalized name: Acellular pertussis vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular pertussis vaccine (Pa)
Study: 9427455
Drug: Whole cell
Normalized name: pertussis, whole cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole cell pertussis vaccine (Pw)
Study: 7705531
Drug: Low-dose monophasic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose monophasic pill
Study: 7705531
Drug: High-dose monophasic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose monophasic pill
Study: 7705531
Drug: No therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No therapy (expectant management)
Study: 2884705
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg tulobuterol/day
Study: 2884705
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg fenoterol/day
Study: 2884705
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment / pretreatment with oral fenoterol
Study: 2884705
Drug: Tulobuterol and
Normalized name: tulobuterol
DrugBank: Tulobuterol (DB12248)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tulobuterol and fenoterol treatment
Study: 30123970
Drug: Ruxolitinib 15
Normalized name: ruxolitinib 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib 15 mg BID plus regorafenib 160 mg QD
Study: 30123970
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus regorafenib 160 mg QD
Study: 24771634
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g ceftriaxone (IV infusion every 12 hours)
Study: 24771634
Drug: Placebo (IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (IV infusion every 12 hours)
Study: 24771634
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g ceftriaxone twice (IV infusion every 12 hours)
Study: 18435883
Drug: Topical rifamycin
Normalized name: rifamycins Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical rifamycin
Study: 18435883
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no rifamycin treatment)
Study: 11525344
Drug: Preparing for
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparing for the Drug‐Free Years (PDFY) curriculum
Study: 8806290
Drug: Co-amoxiclav suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-amoxiclav suspension (20 mg/kg amoxicillin, 5 mg/kg clavulanate potassium), orally three times a day for 14 days
Study: 6371693
Drug: Ritodrine (max
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritodrine (max dose, 350 mcg/min intravenously for 12 hours, then 20 mg orally every 4 hours)
Study: 6371693
Drug: Placebo (intravenously
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (intravenously for 12 hours, then oral therapy)
Study: 30021759
Drug: Low phosphate
Normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low phosphate diet (regular diet plus lanthanum, 750 mg thrice/day, plus 0.7 mmol/kg body wt per day of Na as NaCl)
Study: 24577847
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy delivered by lay providers (BLP), n = 76
Study: 24577847
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy delivered by Ph.D.-level expert providers (PLP), n = 74
Study: 24577847
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy delivered by lay providers (BLP)
Study: 24577847
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy delivered by Ph.D.-level expert providers (PLP)
Study: 22943664
Drug: Endometrial biopsy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endometrial biopsy using a pipelle curette on days 9‐12 and 21‐24 of the menstrual cycle preceding IVF treatment
Study: 15056575
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy for command hallucinations (CTCH)
Study: 9683362
Drug: Sucralfate (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate (1 g six times a day during radiotherapy)
Study: 7530379
Drug: Risperidone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (4 mg dose in caplet form)
Study: 7530379
Drug: Risperidone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (4 mg dose in tablet form)
Study: 22819386
Drug: Pharmacist-initiated medication
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmacist-initiated medication reconciliation
Study: 22819386
Drug: Physician-initiated medication
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Physician-initiated medication reconciliation
Study: 18846487
Drug: Cruciate-sacrificing NexGen
Normalized name: Gentiana cruciata root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cruciate-sacrificing NexGen Full Flex implant
Study: 18846487
Drug: Cruciate-retaining CKS-CC
Normalized name: Gentiana cruciata root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cruciate-retaining CKS-CC knee system
Study: 9012115
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of iodine and selenium
Study: 6712366
Drug: Computer-assisted (CA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-assisted (CA) initial lidocaine hydrochloride therapy
Study: 6712366
Drug: Conventional lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional lidocaine therapy (CT)
Study: 29884676
Drug: Concurrent changes
Normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Canges XP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent changes in kynurenine, quinolinic acid, 3‐hydroxyanthranilic acid, and kynurenine/tryptophan ratio
Study: 26341357
Drug: Enhanced Behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced Behavioral Treatment (EBT)
Study: 20378050
Drug: Active plant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active plant metabolites (e.g., flavonoids, terpenoids, glycosides) as digestive enzyme inhibitors; specific dosage and duration not available.
Study: 20378050
Drug: Currently used
Approvals — FDA: no, EMA: no, PMDA: no
Description: Currently used digestive enzyme inhibitors (bacterial secondary metabolites); specific dosage and duration not available.
Study: 8803529
Drug: Ursodiol (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodiol (600 mg)
Study: 25083614
Drug: Single-dose rabbit
Normalized name: Rabbit
DrugBank: Rabbit (DB10415)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose rabbit antithymocyte globulin (SD-rATG) 6 mg/kg
Study: 25083614
Drug: Divided-dose rabbit
Normalized name: Rabbit
DrugBank: Rabbit (DB10415)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Divided-dose rabbit antithymocyte globulin (divided-dose-rATG)
Study: 25083614
Drug: SD-rATG and
Normalized name: Alphanine SD
DrugBank: Coagulation Factor IX Human (DB13152)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SD-rATG and divided-dose-rATG
Study: 18310205
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (20 ppm, weaned to 2 ppm)
Study: 17077928
Drug: Selective head
Normalized name: Head & Shoulders
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective head cooling with an insulated ice cap, aiming for a target rectal temperature of 35-35.5 degrees C and a target scalp temperature of 10-28 degrees C.
Study: 9186381
Drug: Aspirin (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (160 mg/day) started within 48 hours of onset of suspected acute ischaemic stroke and continued for up to 4 weeks
Study: 3880687
Drug: Labetalol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (400 mg twice a day)
Study: 3880687
Drug: Pindolol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (5 mg twice a day)
Study: 29982097
Drug: Handgrip exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Handgrip exercise (25 repetitions, 3 times daily)
Study: 29982097
Drug: Handgrip exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Handgrip exercise (25 repetitions, 6 times daily)